A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT ID: NCT02065336

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2017-01-31

Brief Summary

The purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.

Detailed Description

Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative intermediates via ribonucleic acid (RNA) interference. The magnitude of the reduction and duration of effect will depend on the dose. Since to date ARC-520 has not been administered to patients with chronic HBV infection, the effective therapeutic dose in patients with chronic HBV infection is unknown. This study is designed to assess the antiviral activity of ARC-520, especially its effect on HBsAg, in patients with chronic HBV infection at different dose levels.

This is a multicenter, randomized, double-blind, placebo-controlled, single-dose escalation study of ARC 520 in combination with entecavir administered to participants with hepatitis B virus e antigen (HBeAg)-negative (Cohorts 1 through 4) or HBeAg-positive (Cohort 5) immune active, chronic HBV infection, followed by a two-dose open-label cohort (Cohort 6), three open-label single-dose cohorts in treatment-naïve participants (Cohorts 7, 11 and 12) and an open-label multi-dose extension study (Cohorts 8, 9, 10). Cohort 6 will investigate ARC-520 in combination with entecavir administered in two doses to participants with HBeAg-positive immune-active chronic HBV infection. Cohorts 7, 11 and 12 will enroll treatment-naïve participants. Cohort 8 will only enroll participants previously completing Cohorts 1-4. Cohort 9 will only enroll participants previously completing Cohort 5 or 6. Cohort 10 will only enroll participants previously completing Cohort 7.

Participants will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate, and temperature), weight, adverse events (AEs), 12-lead electrocardiograms (ECGs), concomitant medication, blood sample collection for hematology, coagulation, chemistry, pharmacokinetic (PK) and exploratory pharmacodynamic (PD) measures, urinalysis, HBV serology, HBV genotyping and sequencing, follicle stimulating hormone (FSH) testing and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the participant is lost to follow-up.

Conditions

Hepatitis B, Chronic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

ARC-520 Cohort 1

a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 2

a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection

Group Type: PLACEBO_COMPARATOR

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 3

a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 4

a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 5

a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

Placebo Normal Saline Cohorts 1-5

a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 6

two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 7

a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 8

open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every \[Q\]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 9

open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 10

open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 11

a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

ARC-520 Cohort 12

a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB

Group Type: EXPERIMENTAL

ARC-520

Intervention Type: DRUG

chlorpheniramine

Intervention Type: DRUG

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

Interventions

ARC-520

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

entecavir

Intervention Type: DRUG

chlorpheniramine

In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.

Intervention Type: DRUG

Other Intervention Names

Baraclude

Eligibility Criteria

Inclusion Criteria

• Diagnosis of HBeAg negative and immune active chronic HBV infection (Cohorts 1-4, 8)
• Diagnosis of HBeAg positive and immune active chronic HBV infection (Cohorts 5-6, 9)
• Diagnosis of HBeAg negative or HBeAg positive and immune active or tolerant chronic HBV infection (Cohorts 7, 10, 11 & 12)
• Patients with > 6 months of continuous, 0.5 mg/day oral entecavir, and a willingness to continue taking entecavir throughout the study (Cohorts 1-6, 8-9).
• Patients naive to entecavir (never on entecavir or on entecavir <30 days prior to screening) and a willingness to take entecavir and willingness to continue taking entecavir throughout the study (Cohorts 7, 11 & 12).

Exclusion Criteria

• Female patients that have a positive pregnancy test or are lactating.
• Acute signs of hepatitis/other infection (eg, moderate fever, jaundice, nausea, vomiting, and abdominal pain) evident within 4 weeks of screening and/or at the screening examination.
• Patients with antiviral therapy other than entecavir within 3 months of screening or prior treatment with interferon or a toll receptor agonist in the last 5 years.
• Use within the last 6 months or an anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants.
• Has any history of autoimmune disease especially autoimmune hepatitis.
• Has human immunodeficiency virus (HIV) infection, as shown by the presence of anti-HIV antibody (sero-positive).
• Is sero-positive for hepatitis C virus (HCV), and/or a history of delta virus hepatitis.
• Has a history of allergy to bee venom or history of hypersensitivity reaction requiring an emergency visit to a physician or hospital and/or requirement for treatment with steroids and/or epinephrine.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ICON Clinical Research

INDUSTRY

Sponsor Role: collaborator

Arrowhead Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bruce Given, MD

Role: STUDY_CHAIR

Arrowhead Pharmaceuticals, Inc.

Locations

Research Site 1

Pokfulam, , Hong Kong

Research Site 2

Shatin, , Hong Kong

Countries

Hong Kong

References

Yuen MF, Wong DK, Schluep T, Lai CL, Ferrari C, Locarnini S, Lo RC, Gish RG, Hamilton J, Wooddell CI, Mak LY, Given BD. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut. 2022 Apr;71(4):789-797. doi: 10.1136/gutjnl-2020-323445. Epub 2021 Mar 12.

Reference Type: DERIVED

PMID: 33712437 (View on PubMed)

Other Identifiers

Heparc-2001

Identifier Type: -

Identifier Source: org_study_id